Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — J.P. Morgan Healthcare Conference 2025
31 slides from Pulse Biosciences's conference presentation, Jan 14, 2025
Slide 1: Corporate Overview January 2025
‘@ Pulse : Biosciences’ Corporate Overview January 2025
Slide 2: Forward Looking Statements
Pulse Biosciences” Forward Looking Statements All statements in this presentation that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's CellFX nsPFA technology and CellFX System to non-thermally clear cells wh
Slide 3: Our Mission
© Our Mission To build a thriving, viable company by providing revolutionary and life-changing therapy for multiple diseases with next-generation Nanosecond Pulsed Field technology.
Slide 4: Surgeon quote on nsPFA potential in cardiac ablation
66 It was immediately clear to me that nanosecond pulsed field ablation (nsPFA) has the potential to not only replace all other energy modalities in cardiac ablation, including radiofrequency and cryo, but due to the speed, safety, and ablation performance of the system, it also has the potential to
Slide 5: Financial Snapshot
Financial Snapshot Strong balance sheet as of 12/31/2024 * Cash and cash equivalents balance $118mm [unaudited] as of December 31°* Pro forma cash and cash equivalents of $130mm including receipts from rights offering * No debt ~2-Year cash runway * Cash burn of approximately $36mm in 2024 * Cash bu
Slide 6: Management and Board of Directors
J Paul LaViolette Kevin Danahy Uecker Mitch Levinson Chief Executive Officer Chief Commercial Officer nology Officer Chief Strategy Officer Co-Chairman of the Board Director ie Medtronic fem BARD D 200 thermagé 3&coolsculpting @NELLCOR INTUITIV RY Established Board of Directors BB Co-Chairman of the
Slide 7: Proprietary Design and Engineering
Proprietary Design and Engineering Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation (nsPFA™) Technology Proprietary Technology Proprietary Treatments Robust Patent Robust Market Entry Only company bringing novel nsPFA enabled Portfolio Initiating 3 IDEs in N
Slide 8: Pulse will create, expand, and upend these markets
Pulse will create, expand, and upend these markets with penetration and global expansion ‘om ¥) Pulse Biosciences’ nsPFA Platform CellFX nsPFA Platform to
Slide 9: Existing ablative therapies have limitations
a * Existing ablative therapies have limitations RF/Heat CRYO/Cold Anew treatment paradigm that allows for: PFA is currently drastically affecting the EP market A fast, efficient treatment t Increased throughput t Increased predictability for scheduling and treatment Safer treatment profile over RF
Slide 10: Micro-PFA Compared to nsPFA for Electrophysiology
Micro-PFA Compared to nsPFA for Electrophysiology Current workflow and case time || BERR: REQUIRED Dd 30 minutes 4-6mm REQUIRED Microsecond (O) Pulse Biosciences: # Configurations Energy deliveries per target Device rotations to “connect the dots” Average ablation time Lesion quality/depth Patient p
Slide 11: Energy + Design Matters
Energy + Design Matters The nsPFA Difference for E Low amplitude > Shallow ablations High amplitude > Deep ablations Long duration > High energy Short duration > Low energy Significant nerve stimulation Much reduced nerve stimulation Cardiac synch and paralytics required No cardiac synch or paralyti
Slide 12: Nanosecond PFA Advantage
Nanosecond PFA Advantage (2) Product designs are purpose built for oO) Nonthermal: no thermal damage or the application spread beyond the electrical field (a) Much lower energy reduces 1) Faster, deep ablations with single electrode design constraints of energy delivery standard PFA . a) Selectively
Slide 13: History of Leading Nanosecond PFA Development
History of Leading Nanosecond PFA Development Pulse Biosciences’ Creating wide and deep IP portfolio covering nsPFA energy and system Continued development and patent filings covering systems, applications, and methods Patent Portfolio 2025 183 103 Issued patents globally Pending patent owned & lice
Slide 14: Direct and Partnership approaches will be determined
Direct and Partnership approaches will be determined for each market based on the opportunity to enter or upend markets with capital efficiency Candidate Markets Candidate Markets Direct Partnership FACTORS INFLUENCING THE STRATEGY INCLUDE: New or established market Scale and simplicity of platforms
Slide 15: Market Entry Strategy
Market Entry Strategy ¢f Thyroid Market Cardiac Surgery AF Ablation $1.3B Addressable Market* $1.8B Addressable Market* $3.0B Addressable Market* Create an untapped Expand usage in Upend the market in Thyroid the Cardiac Surgery EP market market (@) Pulse Biosciences’ ©2025 Pulse Bioscienoas, Ino. A
Slide 16: Thyroid Therapy
Thyroid Therapy arket in Thyroid Opening a new era in therapy for soft tissue ablation such as benign thyroid nodules () PulseBiosciences: ——czsasrusescesens
Slide 17: Benign Thyroid Market Opportunity
Benign Thyroid Market Opportunity nsPFA technology is a new paradigm for surgical patients and watchful waiters created, untapped market Pulse Biosciences’ BTN patients diagnosed in U.S. ~250k345 ~150k ~100k Benign Enter “Watchful thyroidectomies Waiting” $1B+ Annual U.S. TAM
Slide 18: Create an Untapped Market in Thyroid
Thyroid Therapy Create an Untapped Market in Thyroid es Baseline 1 month post
Slide 19: Thyroid Market Development Status
Thyroid Therapy Thyroid Market Development Status Soft Tissue Ablation - FDA Cleared 510(k) Pilot launch underway Launch led by 10 KOL sites to drive adoption Initiating investigator-sponsored research to add clinical data and experience O Pulse Biosciences’
Slide 20: Expanding Usage in the Surgical Cardiac Ablation Market
sanding Usage in the “Surgical Cardiac Ablation ~ Market nsPFA for Surgical AF
Slide 21: Surgical Cardiac Ablation Market Opportunity
Surgical Cardiac Ablation Market Opportunity Pulse Biosciences’ nsPFA technology expands the market ‘Surgical Ablation Annual open-heart procedures in U.S. 300K"! 28% Patients have pre-operative AF 72% Patients at high risk of developing post-op AF"? 216k Future Potential Prophylactic AF Annual U.S.
Slide 22: Expanding Usage in the Surgical Cardiac Ablation Market
Expanding Usage in the Surgical Cardiac Ablation Market
Slide 23: Surgical Cardiac Ablation Status
‘Surgical Ablation Surgical Cardiac Ablation Status Received FDA Breakthrough Device Designation in July 2024 Enrolled in the FDA’s Total Product Life Cycle (TPLC) Advisory Program (TAP) 30 patient multi-center feasibility study underway, expect enrollment completion in Q1 ‘25 Recent publication in
Slide 24: Upending AF Ablation in the EP Market
(D PulseBlosciences: ——czrasrisescnsonos ne. Ashe eaves Upending AF Ablation in the EP Market nsPFA for AF AF Ablation
Slide 25: AF Ablation EP Market Opportunity
AF Ablation EP Market Opportunity AF Ablation 2 Global Atrial EIG EiscinTsel Fibrillation (AF) 1 0-1 5% Disease State: CAGR* al >$aB . Electrophysiol ~1.9M” U.S. patients diagnosed with AF annually nsPFA technology upends the EP market with a novel and differentiated energy Pulse Biosciences’ 22025
Slide 26: Catheter for Pulmonary Vein Isolation
360 Catheter for Pulmonary Vein Isolation
Slide 27: AF Ablation Cardiac Catheter Status
AF Ablation 360 Cardiac Catheter Status Program Updates: * Data read-out of initial 30 treated patients * 3rd site starting in January « Enrollment ongoing in multiple centers — Dr. Natale, Rome, IT AF Symposium Boston, MA, January 16-18, 2025 Friday, January 17th Saturday, January 18th Pulsed Field
Slide 28: Novel Energy, IP, Clinical evidence, IDEs in 2025
Novel Energy IP-183 + 103 Clinical evidence 3 IDEs in 2025 Unique MOA Pulse will own the Mounting and Funded Patent Protected Nanosecond PFA superior Advancing Nonthermal Spas Paradigm shifting Measurable = | | cole | Milestones Target Market Values Portfolio of markets Initializing Strong balance $
Slide 29: AF Ablation Cardiac Catheter Feasibility Study Progress
AF Ablation 360 Cardiac Catheter Feasibility Study Progress Post map after Jessa Dr. Johan Vijgen \ Hasselt’s first case Jessa Hasselt Hospital Pulse Biosciences:
Slide 30: Pulse Biosciences
‘@ Pulse Biosciences’
Slide 31: Citations
Citations Data on file. Thyroidectomy WW Procedure Data provided by iData https://www.ncbi.nim.nih.gov/pme/articles/PMC8215427/ Fine-Needle Aspiration of the Thyroid Gland https://www.ncbi.nlm.nih.gov/books/NBK285544/ CMS - https://www.cms.gov/medicare-coverage-database/view/Ied.aspx?ledid=38968&ve
Pulse Biosciences — J.P. Morgan Healthcare Conference 2025 on 6ix